Marc Schegerin, chief financial officer of ArQule, discusses ArQule’s breakout year including data showing clinical efficacy of ARQ 531 in CLL and the initiation of its MOSAIC trial
Marc Schegerin, chief financial officer of ArQule, on its breakout year and its MOSAIC trial
By Michael Tattory|
2019-10-14T17:28:46-04:00
October 2nd, 2019|Daily Digest, News|Comments Off on Marc Schegerin, chief financial officer of ArQule, on its breakout year and its MOSAIC trial